Review article · 2018

From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles

Michael D. Delost, David T. Smith, Benton J. Anderson, Jón T. Njardarson

Journal of Medicinal Chemistry, 61(24), 10996–11020 · Published 19 July 2018 · DOI 10.1021/acs.jmedchem.8b00876

View at the publisherCite this paper

In brief

“From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles” is a 2018 review article by Michael D. Delost and 3 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 418 citations as of 15 November 2026, which puts it in the top 5% of works published in 2018 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
418
Most cited in
2025 (69)
Field-weighted impact
2.11
References
90
Authors
4

Abstract

Oxygen heterocycles are the second most common type of heterocycles that appear as structural components of U.S. Food and Drug Administration (FDA) approved pharmaceuticals. Analysis of our database of drugs approved through 2017 reveals 311 distinct pharmaceuticals containing at least one oxygen heterocycle. Most prevalent among these are pyranoses, with furanoses, macrolactones, morpholines, and dioxolanes… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018). From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles. Journal of Medicinal Chemistry, 61(24), 10996–11020. https://doi.org/10.1021/acs.jmedchem.8b00876

MLA 9

Delost, Michael D., et al. “From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.” Journal of Medicinal Chemistry, vol. 61, no. 24, 2018, pp. 10996–11020. https://doi.org/10.1021/acs.jmedchem.8b00876.

Chicago

Delost, Michael D., David T. Smith, Benton J. Anderson, and Jón T. Njardarson. 2018. “From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles.” Journal of Medicinal Chemistry 61 (24): 10996–11020. https://doi.org/10.1021/acs.jmedchem.8b00876.

Harvard

Delost, M. D. et al. (2018) ‘From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles’, Journal of Medicinal Chemistry, 61(24), pp. 10996–11020. doi:10.1021/acs.jmedchem.8b00876.

IEEE

M. D. Delost, D. T. Smith, B. J. Anderson, and J. T. Njardarson, “From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles,” Journal of Medicinal Chemistry, vol. 61, no. 24, pp. 10996–11020, 2018, doi: 10.1021/acs.jmedchem.8b00876.

BibTeX

@article{delost2018from,
  title     = {{From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles}},
  author    = {Delost, Michael D. and Smith, David T. and Anderson, Benton J. and Njardarson, Jón T.},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2018},
  volume    = {61},
  number    = {24},
  pages     = {10996--11020},
  doi       = {10.1021/acs.jmedchem.8b00876},
  url       = {https://doi.org/10.1021/acs.jmedchem.8b00876}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201833
20192020
20203838
20214444
20226060
20235757
20246060
20256969
20266767

Its field-weighted citation impact is 2.11: it has been cited 2.11 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • oxygen heterocycles
  • FDA-approved drugs
  • pharmaceuticals
  • epoxides
  • pyranose
  • furanose
  • macrolactones
  • morpholine

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018). From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles. Journal of Medicinal Chemistry, 61(24), 10996–11020. https://doi.org/10.1021/acs.jmedchem.8b00876

How many times has this paper been cited?

418 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Michael D. Delost, David T. Smith, Benton J. Anderson, Jón T. Njardarson.

What is the DOI of this paper?

10.1021/acs.jmedchem.8b00876. The permanent link is https://doi.org/10.1021/acs.jmedchem.8b00876.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.